SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics Closes $37 Million Growth Equity Financing for Commercial Expansion of its SPRINT® PNS System
18. Oktober 2021 09:17 ET | SPR Therapeutics, Inc.
CLEVELAND, Oct. 18, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on providing patients with pain relief without opioids or surgery, announced today it has...
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics CEO Maria Bennett Selected as Winner of EY Entrepreneur of the Year in East Central Region
06. August 2021 10:00 ET | SPR Therapeutics, Inc.
CLEVELAND, Aug. 06, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics is proud to announce that President, Founder and CEO Maria Bennett has been selected as an Ernst & Young (EY) Entrepreneur Of The...
SPR Therapeutics LOGO 361 TM.jpg
Multi-Center Study of SPRINT® PNS System for Chronic Low Back Pain Demonstrates Clinically Significant Improvements in Pain and Quality of Life
12. Juli 2021 08:00 ET | SPR Therapeutics, Inc.
CLEVELAND, July 12, 2021 (GLOBE NEWSWIRE) -- In the largest, most rigorous study to date using the SPRINT® PNS System for chronic axial low back pain (LBP), patients that failed to find relief from...
SPR Therapeutics LOGO 361 TM.jpg
Multi-center Study Demonstrates Significant Reductions in Postoperative Pain and Opioid Use Following Peripheral Nerve Stimulation Treatment
26. April 2021 09:41 ET | SPR Therapeutics, Inc.
CLEVELAND, April 26, 2021 (GLOBE NEWSWIRE) -- Results of a multicenter trial recently published in Anesthesiology, the official peer-reviewed journal of the American Society of Anesthesiologists,...
SPR Therapeutics LOGO 361 TM.jpg
Researchers Unveil a New Theory Explaining Long-term Pain Relief
15. März 2021 09:30 ET | SPR Therapeutics, Inc.
CLEVELAND, March 15, 2021 (GLOBE NEWSWIRE) -- A novel theory recently published in the Journal of Pain Research proposes mechanisms by which a 60-day treatment using percutaneous peripheral nerve...
SPR Therapeutics LOGO 361 TM.jpg
SPRINT® PNS System Demonstrates the Important Role of the Multifidus in Treating Recurrent Low Back Pain Following RFA
02. März 2021 10:45 ET | SPR Therapeutics, Inc.
CLEVELAND, March 02, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, announced publication of clinical data evaluating the impact of...
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics’ CEO Maria Bennett Named as an Entrepreneur Of The Year® 2020 East Central Award Finalist
31. August 2020 12:25 ET | SPR Therapeutics, Inc.
CLEVELAND, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Ernst & Young LLP (EY US) today announced that Maria Bennett, President, CEO and Founder of SPR Therapeutics, Inc.® was named an Entrepreneur Of The...
SPR Therapeutics LOGO 361 TM.jpg
Study of Sprint Peripheral Nerve Stimulation System Demonstrates 12 Months of Low Back Pain Relief Following 60-Day Treatment
21. Januar 2020 08:55 ET | SPR Therapeutics, Inc.
CLEVELAND, Jan. 21, 2020 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, today announced publication of a prospective case series regarding...
SPRINT PNS MicroLead held by physician
Study Demonstrates 12-Month Relief of Post-Amputation Pain Following Treatment With SPRINT PNS System
10. Dezember 2019 08:29 ET | SPR Therapeutics, Inc.
CLEVELAND, Dec. 10, 2019 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, today announced publication of 12-month follow up results of its...
SPRINT PNS MicroLead
SPR Therapeutics Announces 1000th Sprint PNS Procedure
04. Dezember 2019 08:30 ET | SPR Therapeutics, Inc.
CLEVELAND, Dec. 04, 2019 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, announced today the successful commercial placement of its 1000th...